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Breast carcinoma metastasis in a resected meningioma with early
diagnosis of oligometastatic disease: a case report
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Abstract: Tumor-to-tumor metastasis describes the ability of primary tumors to metastasize to other
primary tumors. These events generally occur in aggressive and widely-metastatic disease, with the
appropriate management and significance of these events unknown. A 56-year-old woman with a history
of bilateral, localized, invasive lobular breast carcinoma treated with surgery, systemic therapy, and
adjuvant radiation presented five and two years post-treatment with progressive neurological symptoms.
Imaging revealed an intracranial meningioma, and the patient underwent resection. Pathology revealed
metastatic invasive lobular carcinoma cells within the resected meningioma, and the patient was treated with
postoperative radiation without sequelae. Subsequent staging scans revealed a single osseous lesion suggestive
of oligometastatic disease, and the patient was promptly started on systemic therapy.
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Introduction
Tumor-to-intracranial tumor metastasis is a known but rare
phenomenon, with relatively limited representation in the
literature (1). This scenario is most likely to be witnessed
with indolent tumors being seeded by an aggressive or widely
metastatic carcinoma (2). The most common intracranial
tumors to receive distant metastases are meningiomas,
with breast carcinoma being the most common donor (3).
The incidence of this occurrence is likely underreported,
given the limited ability to evaluate beyond histopathologic
confirmation, the high threshold to pursue neurosurgical
intervention in asymptomatic patients, and increasing
survival times with modern systemic therapies (2). The
significance or mechanism of this process is not completely
understood. In this study, we present the following case of a
56-year-old woman with an intracranial meningioma found
to be seeded by previously-treated breast cancer primaries
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leading to the diagnosis of oligometastatic disease.
We present the following case in accordance with the
CARE reporting checklist (available at http://dx.doi.
org/10.21037/cco-20-122) (4).
Case presentation
The authors are accountable for all aspects of the work in
ensuring that questions related to the accuracy or integrity
of any part of the work are appropriately investigated and
resolved. All procedures performed in studies involving human
participants were in accordance with the ethical standards of
the institutional and/or national research committee(s) and
with the Helsinki Declaration (as revised in 2013).
A 56-year-old female patient presented with left lower
extremity weakness and focal motor seizures. Evaluation
revealed bilateral diplopia for the preceding two months and
headaches for the past week. Her past medical history was
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Figure 1 MRI brain at presentation. Preoperative T1-weighted
post-gadolinium sequence MRI of the brain in the axial plane
demonstrating a 4.9 cm × 6.5 cm × 5.4 cm homogenously-

6.4%. Due to some morphologic overlap with schwannoma,
confirmatory immunohistochemical stains were performed.
Immunohistochemistry for S100 was negative, while EMA
showed mild diffuse immunoreactivity supportive of the
diagnosis of meningioma (Figure 2B). However, there
were rare individual and small clusters of darker-staining
epithelioid cells within the meningioma that were not
otherwise appreciated on the original hematoxylin and eosin
(H&E) stained sections (Figure 2C). By careful alignment
of the EMA-stained cell clusters with the H&E-stained
sections, small linear clusters could be identified that were
morphologically consistent with lobular breast carcinoma.
Breast markers GATA3 and GCDFP-mammaglobin (Figure
2D,E) confirmed the presence of metastatic lobular breast
carcinoma. Additional immunohistochemistry for breast
markers showed these tumor cells were positive for ER and
2+ HER2/Neu staining (Figure 2F). Dual in situ hybridization
for HER2/Neu and PR staining were non-contributory
due to the inability to reliably distinguish rare, scattered,
breast carcinoma cells from meningioma cells, and diffuse
meningioma PR positivity.

enhancing, intracranial mass involving the right greater wing of
the sphenoid with midline shift.

remarkable for bilateral invasive lobular breast carcinoma,
estrogen receptor (ER) and progesterone receptor (PR)
positive, HER2-negative, both treated with surgery,
chemotherapy, radiation, and hormonal therapy five years
(right breast T3N1M0) and two years (left breast T1cN0M0)
prior to presentation, respectively. Magnetic resonance
imaging (MRI) of the brain revealed a large, extra-axial,
homogenously-enhancing mass in the right middle cranial
fossa, measuring 4.9 cm × 6.5 cm × 5.4 cm (Figure 1), with
1.4 cm midline shift and mild bowing of the sphenoid cortex
into the orbit, consistent with meningioma. The patient
underwent image-guided craniotomy with access through
the root of the right zygoma. The mass was devascularized,
sharp resection performed with extensive cauterization of the
surrounding dura, and postoperative computed tomography
(CT) of the head suggestive of gross total resection.
Pathologic findings
The final pathology report of the resected neoplasm
revealed a World Health Organization (WHO) grade I
meningioma (Figure 2A) with a Ki-67 proliferation index of
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Adjuvant treatment and follow up
The patient was referred to radiation oncology for
evaluation of adjuvant radiotherapy (RT) to the resection
cavity. Given the presence of metastatic breast cancer,
stereotactic body radiotherapy (SBRT) was recommended.
MRI was obtained four months after resection, which
revealed significant reduction in the resection cavity and
a questionable, small residual meningeal nodularity in
the posterior resection cavity on T1 post-gadolinium
sequences. She was treated to a total dose of 30 Gy in
five fractions using volumetric modulated arc therapy
(VMAT) in three arcs, flattening-filter-free, prescribed to
the 98.6% isodose line. She completed RT without acute
toxicity, and subsequent complete resolution of presenting
symptoms. PET scan one month after RT revealed a single,
sclerotic, osseous lesion at L3, and she was referred to her
medical oncologist and started on systemic therapy. MRI
of the brain three and six months after RT revealed posttreatment changes without evidence of recurrence (Figure 3).
Repeat staging scans revealed no other areas of disease.
She continued to be without intracranial recurrence and
received systemic therapy until three years after RT, when
she suffered a myocardial infarction and expired. A timeline
of care received by the patient is available in Figure 4.
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Figure 2 Meningioma pathology. Characteristic whorl pattern morphology of meningioma at 100× (A). EMA immunohistochemistry at
400× demonstrating diffuse background staining for the meningioma, along with darker staining lobular breast carcinoma cells (B). Singlefile pattern on H&E within the meningioma suggestive of lobular breast carcinoma at 400× (C). Lobular breast carcinoma cells at 400×
showing immune-reactive for GATA3 (D), GCDFP-Mammoglobulin (E), and HER2Neu (F).

Discussion

Figure 3 Post-treatment MRI brain. T1-weighted post-gadolinium
sequence MRI of the brain six months post radiotherapy in the
axial plane showing significant contraction of the surgical cavity,
curvilinear enhancement, and stable meningeal enhancement along
the craniotomy flap.
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In the 1930s, tumor-to-tumor metastasis to meningioma was
first recorded by Fried BM (5). Of the total cases reported
since, over 70% involved meningiomas, of which nearly
half involved breast cancer metastasis (6). The prevalence
of this phenomenon is postulated to be partly from the
overlapping epidemiology of patients with breast cancer and
meningiomas (7). In addition, the Swedish Cancer Registry
and the United States Surveillance, Epidemiology, and
End Results Program (SEER) reported an increase in the
diagnosis of meningiomas after diagnosis of primary breast
cancer, although this is likely a manifestation of increased
brain imaging (8). Meningiomas are mostly slow-growing,
hypervascular intracranial tumors. Such characteristics
increase the chances of meningeal seeding via hematogenous
spread. They have high lipid and collagen contents and lack
a reactive immune response against foreign bodies, creating
an optimal seeding environment (2,9-11). These factors may
explain why meningiomas are the most common benign
intracranial tumor to accept distant metastases (12).
The relatively increased affinity of metastatic breast
carcinoma cells to meningiomas may also be attributed
to facilitating receptor environments. Estrogen and
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Figure 4 Timeline of events. Timeline of care received by the patient including relevant radiographic imaging, surgeries, and radiotherapies.
MRI, magnetic resonance imaging; VMAT, volumetric modulated arc therapy; PET/CT, positron emission tomography/computed
tomography; RT, radiotherapy.

progesterone receptors found on meningiomas are thought
to be involved in cell-to-cell interactions with breast
carcinoma cells (13). Furthermore, it has been suggested
that breast cancer metastasis is mediated through the
endothelial growth factor receptor (EGFR) family pathway.
HER2-positive breast carcinoma in particular may develop
metastases through HER3 receptor and neuregulin 1
EGFRs (2,14). The HER3-receptor pathway plays a role in
the growth of HER2-positive breast carcinoma cells while
neuregulin 1 is believed to be upregulated on meningioma
cells (14). These described pathways could be relevant for
the mechanism of metastasis in the case presented.
The prognostic impact of tumor-to-tumor metastasis
remains unclear. Unique to our case was the diagnosis
of metastatic disease from meningioma resection and
oligometastatic disease burden upon further work-up. Postsurgical RT in the presented case demonstrated efficacy in
local control. The patient continued to experience relief of
symptoms following surgical resection and RT, and limited
extracranial disease. This outcome is seemingly discordant to
many of the similarly-reported cases. The majority of reviewed
cases describing tumor-to-tumor metastasis from breast
carcinoma to an intracranial meningioma report diffusely
metastatic disease, worsening of presenting symptoms, poor
local control with RT or systemic therapy, and eventual
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mortality, or do not mention outcomes (2,5,7,9-12,14). This
is likely due to the early diagnosis of oligometastatic disease,
rather than heavily pretreated, widely-metastatic disease,
as in other reports. Given the constellation of factors that
facilitate breast-to-meningioma metastases, and low resection
rates of meningiomas among metastatic breast cancer
patients, it is questionable if the prognostic significance, if
any, will ever be elucidated. Patients with prior history of
malignancy, especially breast cancer, who undergo resection
of meningiomas warrant close pathologic examination, even
without history of metastatic disease, as demonstrated by
our case report. Further publications of similar cases should
provide detailed documentation regarding clinical factors,
pathology, extracranial disease status, and prior treatments to
best characterize this phenomenon and factors associated with
their occurrence.
Conclusions
In conclusion, we present a case of tumor-to-tumor metastasis
from invasive lobular breast carcinoma to meningioma
that resulted in the early diagnosis of oligometastatic,
breast cancer. Careful pathologic examination of resected
meningiomas in this patient group is warranted. Future
reports should include detailed information regarding
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patients, pathology, disease control, and treatment history.
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